Predictive factors of anthracycline or taxan based chemotherapy: Analysis from a randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer

被引：0
|
作者：
Ishikawa, Takashi [1 ]
Narui, Kazutaka [1 ]
Shimada, Kazuhiro [1 ]
Kida, Kumiko [1 ]
Sugae, Sadatoshi [2 ]
Ichikawa, Yasushi [2 ]
Tanabe, Mikiko [1 ]
Endo, Itaru [2 ]
Oba, Mari S. [1 ]
机构：
[1] Yokohama City Univ, Med Ctr, Yokohama, Kanagawa 232, Japan
[2] Yokohama City Univ, Clin Oncol & Gastrointestinal Surg, Yokohama, Kanagawa 232, Japan
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-1899
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1899
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer: Kanagawa Breast Oncology Croup (KBOG) 1101 study
    Ishikawa, Takashi
    Shimizu, Daisuke
    Tanabe, Mikiko
    Oba, Mad S.
    Sasaki, Takeshi
    Morita, Satoshi
    Kida, Kumiko
    Nawata, Shuichi
    Mogaki, Masatoshi
    Doi, Takako
    Tsugawa, Koichiro
    Ogata, Haruki
    Kosaka, Yoshimasa
    Sengoku, Norihiko
    Suzuki, Yasuhiro
    Suto, Akihiko
    Chishima, Takashi
    Ichikawa, Yasushi
    Endo, Itaru
    Tokuda, Yutaka
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer. Kanagawa breast oncology group (KBOG) 1101 study
    Ishikawa, T.
    Shimizu, D.
    Tanabe, M.
    Oba, M. S.
    Sasaki, T.
    Morita, S.
    Kida, K.
    Nawata, S.
    Mogami, M.
    Doi, T.
    Tsugawa, K.
    Ogata, H.
    Kosaka, Y.
    Sengoku, N.
    Saito, Y.
    Suzuki, Y.
    Suto, A.
    Chishima, T.
    Ichikawa, Y.
    Endo, I.
    Tokuda, Y.
    CANCER RESEARCH, 2013, 73
  • [3] A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
    Yoo, Changhoon
    Kim, Sung-Bae
    Ahn, Jin-Hee
    Kim, Jeong Eun
    Jung, Kyung Hae
    Gong, Gyung-Yub
    Son, Byung-Ho
    Ahn, Sei-Hyun
    Ahn, Seung Do
    Kim, Hak-Hee
    Shin, Hee Jung
    Kim, Woo Kun
    CANCER RESEARCH AND TREATMENT, 2015, 47 (03): : 406 - 415
  • [4] A phase II trial of neoadjuvant docetaxel/cyclophosphamide followed by epirubicin/cyclophosphamide for triple-negative breast cancer
    Tanaka, N.
    Hirano, A.
    Inoue, H.
    Ogura, K.
    Hattori, A.
    Jibiki, N.
    Yukawa, H.
    Matsuoka, A.
    Kodera, A.
    Kamimura, M.
    Naritaka, Y.
    Shimizu, T.
    CANCER RESEARCH, 2017, 77
  • [5] A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer
    Schneeweiss, A.
    Marme, F.
    Ruiz, A.
    Manikhas, A. G.
    Bottini, A.
    Wolf, M.
    Sinn, H. -P.
    Mansouri, K.
    Kennedy, L.
    Bauknecht, T.
    ANNALS OF ONCOLOGY, 2011, 22 (03) : 609 - 617
  • [6] The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients
    Wu, Xian
    Ye, Chaoran
    Wang, Xingmeng
    Cai, Ruyu
    Yang, Junzhe
    Yu, Xiafei
    Zhou, Yi
    Shen, Li
    Zhu, Yanhui
    Liu, Xiaoan
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 1517 - 1527
  • [7] Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy for Patients with Primary Breast Cancer
    Iwata, Hiroji
    Sato, Nobuaki
    Masuda, Norikazu
    Nakamura, Seigo
    Yamamoto, Naohito
    Kuroi, Katsumasa
    Kurosumi, Masafumi
    Tsuda, Hitoshi
    Akiyama, Futoshi
    Ohashi, Yasuo
    Toi, Masakazu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (07) : 867 - 875
  • [8] A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study
    Narui, K.
    Ishikawa, T.
    Shimizu, D.
    Tanabe, M.
    Sasaki, T.
    Oba, M. S.
    Morita, S.
    Nawata, S.
    Kida, K.
    Mogaki, M.
    Doi, T.
    Tsugawa, K.
    Ogata, H.
    Ota, T.
    Kosaka, Y.
    Sengoku, N.
    Kuranami, M.
    Saito, Y.
    Suzuki, Y.
    Suto, A.
    Arioka, H.
    Chishima, T.
    Ichikawa, Y.
    Endo, I.
    Tokuda, Y.
    CANCER RESEARCH, 2017, 77
  • [9] Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer
    Chen, Xiaosong
    Ye, Guolin
    Zhang, Chenfang
    Li, Xinzheng
    Chen, Yiding
    Xie, Xiaohong
    Zheng, Hong
    Cao, Yali
    Wu, Kejin
    Ni, Duo
    Tang, Jinhai
    Wei, Ziguo
    Shen, Kunwei
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 142 (03) : 549 - 558
  • [10] Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer
    Xiaosong Chen
    Guolin Ye
    Chenfang Zhang
    Xinzheng Li
    Yiding Chen
    Xiaohong Xie
    Hong Zheng
    Yali Cao
    Kejin Wu
    Duo Ni
    Jinhai Tang
    Ziguo Wei
    Kunwei Shen
    Breast Cancer Research and Treatment, 2013, 142 : 549 - 558
12345